Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)

Avalo Therapeutics filings provide 10 years of FCF Margin readings, the most recent being 24216.95% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1638153.0% to 24216.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 10300.0%, a 82381.0% increase, with the full-year FY2025 number at 87288.14%, down 7616433.0% from a year prior.
  • FCF Margin hit 24216.95% in Q4 2025 for Avalo Therapeutics, down from 7835.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 37.67% in Q3 2022 to a low of 24216.95% in Q4 2025.
  • Median FCF Margin over the past 5 years was 1714.77% (2023), compared with a mean of 4025.33%.
  • Biggest five-year swings in FCF Margin: soared 737305bps in 2022 and later tumbled -1638153bps in 2025.
  • Avalo Therapeutics' FCF Margin stood at 7812.79% in 2021, then soared by 94bps to 439.73% in 2022, then fell by -10bps to 484.41% in 2023, then crashed by -1518bps to 7835.42% in 2024, then crashed by -209bps to 24216.95% in 2025.
  • The last three reported values for FCF Margin were 24216.95% (Q4 2025), 7835.42% (Q4 2024), and 4629.32% (Q3 2024) per Business Quant data.